High-Dose Inhaled Nitric Oxide in Acute Hypoxemic Respiratory Failure Due to COVID-19: A Multicenter Phase II Trial
Raffaele Di Fenza(Harvard University), Lorenzo Berra(Massachusetts General Hospital), Ariel Mueller(Harvard University), Vibhu Parcha(University of Alabama at Birmingham), L. Keith Scott(Louisiana State University Health Sciences Center Shreveport), Sabrina Paganoni(Harvard University), Oluwaseun Akeju(Brigham and Women's Hospital), Edward A. Bittner(Harvard University), Jonathan Z. Li(Brigham and Women's Hospital), Bijan Safaee Fakhr(University of Alabama at Birmingham Hospital), Stefano Gianni, Olof Wall(Karolinska Institutet), Somnath Bose(Prime University), Magnus Hedenstierna(Danderyds sjukhus), Fumito Ichinose(Harvard University), Daniel C. Törnberg, Timothy T. Houle(Massachusetts General Hospital), Pankaj Arora(University of Oxford), Peggy S. Lai(Harvard University), Ryan W. Carroll(Northwestern University), Piotr Harbut, Valentina Giammatteo(Harvard University), Stefano Cenci(Harvard University), Naman S. Shetty(University of Alabama at Birmingham)
American Journal of Respiratory and Critical Care Medicine
September 29, 2023
Cited by 46
Related Papers
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
SARS-CoV-2 viral load is associated with increased disease severity and mortality
|Nature Communications|2020|981
Detection of SARS-CoV-2 with SHERLOCK One-Pot Testing
|New England Journal of Medicine|2020|801
Inhaled Nitric Oxide
|Circulation|2004|533
Evidence for brain glial activation in chronic pain patients
|Brain|2015|499